Evidence map›Paper›PMID 32581232›Full record

ArticleScientific reports2020

Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma.

Wilson I Gonsalves, Katarzyna Broniowska, Erik Jessen, Xuan-Mai Petterson, Alexander Graham Bush, Jaimee Gransee, Martha Q Lacy, Taro Hitosugi, Shaji K Kumar

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Progress in metabolomics of multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Wilson I GonsalvesThe Division of Hematology, Mayo Clinic, Rochester, MN, United States. gonsalves.wilson@mayo.edu.
Katarzyna BroniowskaMetabolon Inc, Morrisville, NC, Mayo Clinic, Rochester, MN, United States.
Erik JessenBiostatistics and Informatics, Mayo Clinic, Rochester, MN, United States.
Xuan-Mai PettersonEndocrinology and the Department of Oncology, Mayo Clinic, Rochester, MN, United States.
Alexander Graham BushEndocrinology and the Department of Oncology, Mayo Clinic, Rochester, MN, United States.
Jaimee GranseeEndocrinology and the Department of Oncology, Mayo Clinic, Rochester, MN, United States.
Martha Q LacyThe Division of Hematology, Mayo Clinic, Rochester, MN, United States.
Taro HitosugiMolecular Therapeutics, Mayo Clinic, Rochester, MN, United States.
Shaji K KumarThe Division of Hematology, Mayo Clinic, Rochester, MN, United States.
Mayo Clinic · USMayo Clinic in Arizona · USWinnMed · USMetabolon (United States) · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
TECHNOLOGY NMR SPECTROSCOPYU24DK100469 · NIDDK · MAYO CLINIC ROCHESTER · PI NAIR, K SREEKUMARAN · 2013 to 2017
$9.0M
Onset and biomarkers for progression of monoclonal gammopathiesR01CA168762 · NCI · MAYO CLINIC ROCHESTER · PI KUMAR, SHAJI KUNNATHU, RAJKUMAR, S VINCENT · 2012 to 2024
$3.2M
Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple MyelomaK23CA218742 · NCI · MAYO CLINIC ROCHESTER · PI GONSALVES, WILSON · 2017 to 2019
$513k
NCATS NIH HHS UL1 TR000135NCI NIH HHS K23 CA218742NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA168762NIDDK NIH HHS U24 DK100469
6 · The paper itself

Abstract

Oncogenic drivers of progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) such as c-MYC have downstream effects on intracellular metabolic pathways of clonal plasma cells (PCs). Thus, extracellular environments such as the bone marrow (BM) plasma likely have unique metabolite profiles that differ from patients with MGUS compared to MM. This study utilized an untargeted metabolite and targeted complex lipid profiling of BM plasma to identify significant differences in the relative metabolite levels between patients with MGUS and MM from an exploratory cohort. This was followed by verification of some of the metabolite differences of interest by targeted quantification of the metabolites using isotopic internal standards in the exploratory cohort as well as an independent validation cohort. Significant differences were noted in the amino acid profiles such as decreased branch chain amino acids (BCAAs) and increased catabolism of tryptophan to the active kynurenine metabolite 3-hydroxy-kynurenine between patients with MGUS and MM. A decrease in the total levels of complex lipids such as phosphatidylethanolamines (PE), lactosylceramides (LCER) and phosphatidylinositols (PI) were also detected in the BM plasma samples from MM compared to MGUS patients. Thus, metabolite and complex lipid profiling of the BM plasma identifies differences in levels of metabolites and lipids between patients with MGUS and MM. This may provide insight into the possible differences of the intracellular metabolic pathways of their clonal PCs.

Indexed as

Amino Acids, Branched-ChainDiagnosis, DifferentialHumansKynurenineLactosylceramidesLipidomicsMetabolomicsMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaPhosphatidylethanolaminesPhosphatidylinositolsPlasma CellsProspective StudiesAmino Acids, Branched-ChainKynurenineLactosylceramidesPhosphatidylethanolaminesPhosphatidylinositols

Identifiers

PMID32581232
PMCPMC7314797
OpenAlexW3037644708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.